Serotonin2A receptor blockade and clinical effect in first-episode schizophrenia patients treated with quetiapine

We have previously reported decreased frontal cortical serotonin2A receptor binding in 30 antipsychotic na < ve first-episode schizophrenic patients and a relationship between this binding and positive psychotic symptoms. Until now, no longitudinal studies of serotonin2A receptor in first-episode antipsychotic-na < ve schizophrenia patients have reported on the relationship between serotonin2A receptor occupancy and treatment effect after sustained treatment with a specific atypical antipsychotic compound. Here, we measured serotonin2A receptor occupancy with [F-18]altanserin PET in 15 first-episode antipsychotic-na < ve schizophrenia patients before and after 6 months of quetiapine treatment. Moreover, we investigated possible relationships between clinical efficacy, oral dose, and plasma levels of quetiapine Significant nonlinear relationships were found between serotonin2A receptor occupancy, quetiapine dose, and plasma concentration. There was a modest effect on positive symptoms up until a serotonin2A receptor occupancy level of approximately 60%. A receptor occupancy level between 60% and 70% appeared to exert the optimal serotonin2A receptor related treatment effect on positive symptoms whereas no additional serotonin2A receptor associated treatment effect was obtained above a receptor occupancy of 70%. Taken together, the data point to a therapeutic role of the serotonin2A receptor in the treatment of subgroups of patients with schizophrenia. Specifically, the study indicates a serotonin2A receptor associated therapeutic window on positive symptoms in responding patients in the range between 60% and 70% occupancy in antipsychotic-na < ve first-episode schizophrenia. We speculate that non-responding patients need higher dopamine D-2 receptor blockade. Future studies with concurrent measurement of interactions with the dopamine system are, however, warranted to clarify this.